Cross-institution positioning
Jan 23, 2026Mixed positioning. No institution has two comparable Schedule 13 observations yet.
Source: Schedule 13 researchBCTX Institutional Ownership
BriaCell Therapeutics Corp.
Latest stored close $3.92 as of Oct 8, 2026 View live quote ↗
STOCKNODE Outlook
Neutral
51/100
1 tracked · 0 comparable
Latest filing
Jan 23, 2026
Positive breadth
1 positive · 0 negative
Recent close
$3.92
Research confidence
Limited
Institutional Research 56/100 · 0 accumulating · 0 reducing / exited
Ownership history
Reported ownership % history
Latest filing Jan 23, 2026
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
Locked preview
Unlock the reported ownership timeline
Unlock full research
Accumulating0
Newly reported1
Reducing / exited
0
52-week position
—
Institutional Intelligence
Why STOCKNODE says Neutral
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
STOCKNODE Outlook
Neutral 51/100
Confidence:Limited
Why this signal
- 0 tracked institutions accumulating versus 0 reducing/exited.
Institutional
56/100
Fundamentals
33/100
Events
50/100
Material company events
Jun 26, 2026Latest classified evidence: Regulation FD disclosure. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataSEC fundamentals
Jun 9, 2026Net income -16.9% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsPrice context
Sep 15, 2026Recent close is 8% through its reported 52-week range; -55.7% over one year.
Source: Stored historical price series
Latest filing decision brief
Investor / Pro
Research the latest Initial Schedule 13G from Citadel Advisors.
Filed Jan 23, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
Supporting institutional evidence
Institutional Evidence
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
Latest filing
Jan 23, 2026
Latest reported position changes
Investor / Pro detailSee each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Citadel Advisors
Filed Jan 23, 2026
Direction locked
Unlock the actual direction, share change, ownership change, and classification basis.
No premium position values are sent in this locked preview.
Unlock full research
Reported direction breadth by as-of date
Locked previewComparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Unlock actual accumulation vs. reduction breadth across reported position dates.
View plans
Institution comparison
Investor / Pro detailCompare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Citadel Advisors
Filed Jan 23, 2026
Unlock the evidence behind the score
Know who changed position, by how much, and when the SEC learned about it.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
✓ Actual share and ownership changes
✓ Position as-of date vs. SEC filed date
✓ Deterministic direction basis
✓ Full evidence on every eligible stock
SEC company-event context
Material company events
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
30-day material events0
90-day capital-related0
90-day equity-related0
90-day debt-related0
View recent company-event filing evidence
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Jun 26, 2026 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Jun 3, 2026 | 8-K | 1.01, 3.02, 8.01, 9.01 | Material definitive agreement; Unregistered sale of equity securities; Other event; Financial statements / exhibits | Equity | Filing |
| Jun 2, 2026 | 424B5 | — | Prospectus filing | Capital-related | Filing |
| Mar 31, 2026 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Mar 9, 2026 | 8-K | 5.07 | Shareholder vote results | — | Filing |
| Feb 20, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
| Jan 15, 2026 | 8-K | 1.01, 8.01, 9.01 | Material definitive agreement; Other event; Financial statements / exhibits | — | Filing |
| Jan 14, 2026 | 424B4 | — | Prospectus filing | Capital-related | Filing |
| Dec 29, 2025 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Dec 23, 2025 | S-1 | — | Securities registration statement | Capital-related | Filing |
| Dec 1, 2025 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
SEC-reported company fundamentals
Fundamentals
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
Operating income
$-7.6M
Q3 2026
-20.4% YoY 10-Q filed Jun 9, 2026
Net income
$-7.2M
Q3 2026
-16.9% YoY 10-Q filed Jun 9, 2026
Diluted EPS
$-0.99
Q3 2026
+94.0% YoY 10-Q filed Jun 9, 2026
Operating cash flow
$-22.7M
YTD through Apr 30, 2026
-13.2% YoY 10-Q filed Jun 9, 2026
Free cash flow
$-22.8M
YTD through Apr 30, 2026
10-Q filed Jun 9, 2026
Cash & equivalents
$6.9M
As of Apr 30, 2026
-44.8% YoY 10-Q filed Jun 9, 2026
Assets
$27.1M
As of Apr 30, 2026
+59.2% YoY 10-Q filed Jun 9, 2026
Stockholders’ equity
$23.4M
As of Apr 30, 2026
+96.0% YoY 10-Q filed Jun 9, 2026
Shares outstanding
8.7M
As of Jun 9, 2026
+28.4% YoY 10-Q filed Jun 9, 2026
Current market context
Price performance
Dated price context from the historical market series already collected for this security.
Recent stored close
$3.58
View live quote ↗
52-week low
$2.60
Jun 11, 2026
52-week high
$14.68
Oct 21, 2025
Below 52-week high
75.6%
1W return
0.0%
1M return
+4.1%
3M return
+30.7%
6M return
-15.2%
YTD return
-49.6%
1Y return
-55.7%
30-day volatility
80.3%
90-day volatility
87.3%
1Y max drawdown
-80.1%
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
How to read Schedule 13 ownership changes
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
Current ownership filings and reported ownership changes are available on free access. Investor and Pro add filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and alerts. The overall institutional consensus preview remains public. Compare plans.
Beneficial ownership filing history
Showing 2 of 2 filing(s)View beneficial ownership filing evidence
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Citadel Advisors CIK0001423053 | Jan 15, 2026 observed Jan 23, 2026 filed · 8d Initial Schedule 13G | Initial Schedule 13G | 717.2K | 9.99% | $4.49 | $4.35 | $3.92 |
| Citadel Advisors CIK0001423053 | Sep 30, 2025 quarter end Nov 14, 2025 filed Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 11.1K | $3.92 |
Explore more institutional activity
Related research
Compare BCTX with other securities showing similar institutional activity or recent accumulation across several tracked institutions.